Colostrum Market Gains Strategic Momentum of USD 5.71 Billion by 2035 as Performance Nutrition and Medical Applications Accelerate Global Growth

This is a paid press release. Contact the press release distributor directly with any inquiries.Future Market Insights, Inc. 6 min read Rising demand for immunity, gut health, and performance nutrition is reshaping the global colostrum market across supplements, infant nutrition, and clinical use. NEWARK, DELAWARE / ACCESS Newswire / February 9, 2026 / The global colostrum market is entering a decisive growth phase, driven by expanding applications in sports nutrition, immunity support, infant formula, and emerging medical nutrition. Sales of colostrum are valued at USD 3.19 billion in 2025 and are projected to reach USD 5.71 billion by 2035, advancing at a 6.0% CAGR over the forecast period. This growth reflects a broader consumer pivot toward bioactive, naturally sourced ingredients with clinically supported benefits.Powdered bovine colostrum continues to anchor the category, accounting for nearly two-thirds of 2025 sales, owing to its stability, scalability, and ability to preserve immunoglobulins, lactoferrin, and growth factors. Its dominance highlights how formulation efficiency and functional integrity remain central to buyer decisions across nutraceutical and infant-nutrition supply chains. Performance Nutrition Fuels Category AccelerationColostrum’s fastest gains are being recorded in performance and sports nutrition, where immune resilience, gut integrity, and recovery are core value propositions. SPINS retail analytics reported a 155% year-on-year increase in sports-nutrition products containing colostrum, marking it as the fastest-growing ingredient within the segment.This momentum has attracted mainstream brands. In January 2025, Vital Proteins launched colostrum capsules, extending its collagen franchise toward immune-health consumers, as reported by Nutraceuticals World. The move reflects how established players are repositioning colostrum beyond niche wellness into everyday functional supplementation.Innovation and Capital Reallocation Reshape Competitive StrategiesStrategic product innovation is intensifying. In November 2024, PanTheryx introduced Relesium, a patented colostrum-egg formulation targeting gastrointestinal discomfort associated with GLP-1 medications. Commenting on the launch, Tom Feeley stated that the product addresses “a largely untapped market” of millions of GLP-1 users seeking digestive support.At the corporate level, Fonterra has signaled a sharper focus on high-value B2B nutrition ingredients. CEO Miles Hurrell confirmed in November 2024 that both a trade sale and an IPO of its consumer unit were under consideration, allowing capital redeployment toward advanced nutrition solutions, according to Reuters. This shift underscores how suppliers are prioritizing margins, science-backed differentiation, and long-term demand stability.Regulatory Oversight Strengthens Market CredibilityRegulatory vigilance is reinforcing consumer trust. In May 2024, the U.S. Food and Drug Administration tested 297 retail dairy sam Read More